Recently, South Korean idol Song Joong Ki endorsed SD BIOSENSOR, an in vitro diagnostic company, sparking heated discussions in the IVD industry.

 

SDB was established as a separate company by a division of Standard Diagnostics Inc at the end of 2010. SD was established in 1999. It mainly produces rapid diagnostic reagents, enzyme-linked immunoassay reagents, urine test reagents, biosensors and raw materials. In 2006, SD was listed on the Korean stock market. By June 2010, its market value reached 300 billion won, or approximately 280 million US dollars.

 

SD BIOSENSOR is a global leader in the development and commercialization of innovative in vitro diagnostic products in the field of rapid POCT testing, especially focusing on POCT rapid testing, immunodiagnosis, molecular diagnostics and blood glucose monitoring products. The cooperation with Song Joong Ki helps SDB to quickly open the home self-inspection market for COVID-19 testing.

 

During the epidemic, SDB quickly developed COVID-19 test reagents. Its antibody tests obtained FDA emergency use authorization, and its COVID-19 antigen tests were listed in the WHO EUL. The COVID-19 antigen home-use teats developed in cooperation with Roche obtained CE certification, which helped Roche develop rapid POST tests. In the first quarter of 2021, the revenue of Roche's POCT products related to COVID-19 business reached 716 million francs. In 2020, the rapid antigen products also has more than 500 million francs of revenue.

 

In addition, as early as February 8, 2012, Fosun Pharma and SD formally signed a cooperation agreement to participate in SD company and hold 17.65% of the equity, becoming the agent of SD Biosensor in China.